Experience with pegylated interferon α -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients

Krisstina Gowin, Prakash Thapaliy, Jan Samuelson, Claire Harrison, Deepti Radia, Bjorn Andreasson, John Mascarenhas, Alessandro Rambaldi, Tiziano Barbui, Catherine J. Rea, John Camoriano, Amy Gentry, Jean Jacques Kiladjian, Casey O'Connell, Ruben Mesa

Research output: Contribution to journalArticle

57 Scopus citations

Abstract

The Philadelphia negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis, are associated with substantial vascular and transformative complications. Standard therapy for high-risk disease, particularly in patients that have failed initial therapy, remains controversial. Non-pegylated interferon has previously been shown to be effective in controlling erythrocytosis, thrombocytosis and thrombotic complications, but was found to have poor tolerability and excessive adverse effects. Recently, pegylated interferon alpha-2a was introduced and found to be better tolerated and less toxic than standard interferon. In addition, in recent phase II trials, pegylated interferon alpha-2a therapy was found to induce both hematologic and molecular remissions. We retrospectively analyzed 118 myeloproliferative patients who underwent pegylated interferon alpha-2a treatment. Responses were evaluated by ELN, IWG-MET and EUMNET standardized criteria sets and adverse effects were analyzed.

Original languageEnglish (US)
Pages (from-to)1570-1573
Number of pages4
JournalHaematologica
Volume97
Issue number10
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

Keywords

  • Myeloproliferative neoplasms
  • Pegylated interferon alpha-2a
  • Response

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Experience with pegylated interferon α -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients'. Together they form a unique fingerprint.

  • Cite this

    Gowin, K., Thapaliy, P., Samuelson, J., Harrison, C., Radia, D., Andreasson, B., Mascarenhas, J., Rambaldi, A., Barbui, T., Rea, C. J., Camoriano, J., Gentry, A., Kiladjian, J. J., O'Connell, C., & Mesa, R. (2012). Experience with pegylated interferon α -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica, 97(10), 1570-1573. https://doi.org/10.3324/haematol.2011.061390